Glutamate receptor metabotropic 7 (GRM7) gene polymorphisms in mood disorders and attention deficit hyperactive disorder.
L-glutamate is the chief excitatory neurotransmitter in the central nervous system (CNS) which activates metabotropic receptors including the metabotropic glutamate receptor GRM7. Single nucleotide polymorphisms (SNPs) within GRM7 gene have been associated with several psychiatric conditions. In the present study, we assessed association between two GRM7 SNPs (rs6782011 and rs779867) and two neuropsychiatric disorders including attention deficit hyperactive disorder (ADHD) and mood disorders. There were no significant differences in genotype, allele and haplotypes frequencies of the rs6782011 and rs779867 between bipolar disorder 1 (BPD1) patients and controls. The CC genotype of the rs6782011 was significantly associated with BPD2 in recessive model (OR (95% CI) = 1.78 (1.09-2.91), adjusted P value = 0.04) and with ADHD in dominant and co-dominant models (OR (95% CI) = 1.98 (1.11-3.53), adjusted P value = 0.04; OR (95% CI) = 2.27 (1.23-4.17), adjusted P value = 0.04 respectively). The C G haplotype (rs6782011 and rs779867 respectively) was more prevalent among both BPD2 patients (OR (95%CI) = 2.03 (1.36-3.01), adjusted P value = 0.002) and MDD patients (OR (95%CI) = 2.08 (1.37-3.16), adjusted P value = 0.002) compared with controls. The current study provides further evidences for participation of GRM7 variants in conferring risk of neuropsychiatric disorders.